Fibrotic lung disease, nighttime oxygen drops, and exercise oxygen drops
Part of Heart & circulation, Lungs & breathing clinical trials.
This study looks at how lung scarring affects oxygen levels during sleep and exercise. It may help find better ways to monitor and treat breathing problems in people with fibrotic interstitial lung disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a type of fibrotic lung scarring (like IPF or chronic hypersensitivity pneumonitis) with at least 10% scarring on CT scan.
- You are not currently using or needing long-term oxygen therapy.
- You do not have moderate or severe sleep apnea (pauses in breathing during sleep).
- You do not have pulmonary hypertension (high blood pressure in the lungs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
This study is for people with a specific type of lung scarring (not IPF) to understand how the disease progresses. Researchers will collect detailed health information, imaging, and blood samples to learn more about the condition.
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
This study looks at how well skeletal (muscle) function supports exercise in people with interstitial lung diseases (including idiopathic pulmonary fibrosis). It may help better understand fitness and breathing limits, which can guide rehabilitation choices and future care.
This study follows patients with chronic lung scarring (fibrosing interstitial lung disease) who are in the intensive care unit for severe breathing failure. It aims to better understand their condition and care, which may help improve future treatments.
This trial tests whether starting anti-scarring medication early helps people with a type of lung scarring called fibrotic interstitial lung disease (ILD) that hasn't gotten worse. The goal is to see if it can prevent further damage and improve breathing.
Hear when a new Interstitial Lung Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.